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Toxicogenomics: Toward the Future of Toxic Tort Causation
Jon R. Pierce and Terrence Sexton'
I. Introduction
Plaintiff suspects that a chemical in her city's water supply
has caused her to develop a rare form of liver cancer. Defendant, a
company in Plaintiff s city, has been discharging the chemical into
the water for a number of years. Both parties in the toxic tort
litigation are at the mercy of an unevenly developed and often-
insufficient body of science to establish or rebut the required
causation element.
This article will examine the current causation paradigm in
toxic tort litigation, pointing out its specific weaknesses. The
article will then introduce an emerging discipline, toxicogenomics,
which will eventually make it possible to specifically describe the
molecular pathways leading from exposure to injury, and in so
doing will greatly improve the reliability of causation evidence in
toxic tort cases to the benefit of both plaintiffs and defendants. To
illustrate its potential usefulness, this article will walk through a
hypothetical toxicogenomics experiment involving a suspected
liver toxin. The article will conclude by suggesting that judges
controlled by Daubert v. Merrell Dow Pharmaceuticals, Inc.
2
would be wise not to admit such evidence until more research can
definitively link the described molecular pathways to the specific
injury.
Jon R. Pierce, J.D. Candidate, University of North Carolina School of Law,
2004. Terrence Sexton is a trial attorney with the international law firm of
Shook Hardy & Bacon LLP. He represents clients nationwide in cases
involving toxic torts, products liability, white collar crime and commercial
disputes. Mr. Sexton received his Juris Doctor from St. Louis University Law
School and his Bachelor of Arts from Rockhurst College.
2 509 U.S. 579 (1993).
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I. Current Causation Paradigm in Toxic Tort Litigation
It is a fundamental premise of tort law that a plaintiff must
establish that the defendant's acts or omissions proximately caused
her injury in order to prevail. Historically, a variety of inexact
tools have been used to attempt to establish a causal link between a
substance and an adverse effect.4 A plaintiff in toxic tort litigation
must prove, by a preponderance of the evidence, both that the
substance at issue could cause the general type of injury suffered
(general causation) and that it did cause her injury (specific or
individual causation).5 Clearing both of these evidentiary hurdles
currently is a significant challenge. It is often so daunting that
some plaintiffs opt instead to pursue novel causes of action.6 If
validated by the scientific community, toxicogenomics could
become an important tool for plaintiffs and defendants alike.
3 See, e.g., James Pizzirusso, Increased Risk, Fear of Disease and Medical
Monitoring: Are Novel Damage Claims Enough to Overcome Causation
Difficulties in Toxic Torts?, 7 ENVTL. LAW. 183, 186 (2000).
4 Mark Geistfeld, Scientific Uncertainty and Causation in Tort Law, 54 VAND.
L. REV. 1011, 1012 (2001). The traditionally available tools generally have
involved observing "health outcomes in populations of animals exposed to large
amounts of the substance, study[ing] the biochemical effects of the substance on
cells, organs, and embryos, [or] compar[ing] the substance's chemical
composition to other known health hazards." Id.
5 Carl F. Cranor & David A. Eastmond, Article: Scientific Ignorance and
Reliable Patterns of Evidence in Toxic Tort Causation: Is There a Need for
Liability Reform, 64 LAW & CONTEMP. PROB. 5, 15 (2001); see also Joseph
Sanders & Julie Machal-Fulks, Article: The Admissibility ofDifferential
Diagnosis Testimony to Prove Causation in Toxic Tort Cases: The Interplay of
Adjective and Substantive Law, 64 LAW & CONTEMP. PROB. 107, 110 (2001);
Andrew See, Use of Human Epidemiology Studies in Proving Causation, 67
DEF. CouNs. J. 478, 479 (2000).
6 Pizzirusso, supra note 3 (describing the history, policies, and specific
examples of novel causes of action such as "fear of' a disease, "increased
risk" of a disease, and "medical monitoring"); cf Norfolk & Western
Railway Co., v. Freeman Ayers, 538 U.S. 135 (2003) (recognizing that a
defendant who has already been found liable to a plaintiff for causing her
asbestosis (asbestosis causation established), may also be liable to that
same defendant for emotional distress damages based on a reasonable and
genuine fear of eventually developing cancer (cancer causation not
established)).
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A. General Causation
To prove general causation, plaintiffs often proffer
epidemiological evidence. Indeed, some cases have even required
epidemiology studies to satisfy the general causation burden. In
any epidemiology study, "subsets or samples of populations" are
examined "to determine whether there is an association between
exposure to a substance or factor and subsequent disease or
injury.' ' 8 In general, "large-scale" epidemiology studies can be
probative as to whether a chemical or other potentially toxic
substance can cause an injury since they involve either "comparing
the incidence of adverse health outcomes in groups of exposed and
non-exposed individuals, or comparing the incidence of exposure
across injured and healthy groups. 9
Unfortunately, epidemiology studies "are expensive, time-
consuming, and require that a large number of people be exposed
to the substance."' 0 Given the current capabilities and limitations
of science, however, "the hazardous properties of [many]
substance[s] often cannot be established" via any other
mechanism." Simply put, the existence of epidemiology studies
may be the only avenue to meet the general causation burden in a
toxic tort case. Furthermore, unless and until a party establishes
general causation, any evidence regarding specific or individual
causation likely would be deemed irrelevant and inadmissible.' 2
B. Specific Causation
Another major limitation of epidemiology studies is that
they "are relevant only to general causation" since results from
such studies cannot establish whether a particular exposure or
series of exposures actually caused the disease or injury in a
7 See, supra note 5, at 479. However, epidemiological studies may not be
necessary if a "causal mechanism for the disease" is known. Id.
8 Id. at 478.
9 Geistfeld, supra note 4, at 1012.
1o 1d; see also Chrisitiana P. Callahan, Molecular Epidemiology: Future Proof
of Toxic Tort Causation, 8 ENVTL. LAW. 147, 162 (2001).
" Geistfeld, supra note 4, at 1012.
12 See, supra note 5, at 478.
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specific individual. 13 Determining specific causation often is much
more difficult than establishing general causation.14 Additionally,
the complex etiology of many diseases creates the possibility that
any of a variety of factors could have caused the plaintiff s
injury. 15
To sort through the myriad possible causes of injury, courts
often rely on a physician performing a differential diagnosis
16
where the physician, as an expert witness, considers and rules out
potential causes of injury, finally stating an opinion as to whether
the particular substance at issue caused the plaintiff's injury.' 7
Despite advances in medical science, there still are significant
limitations to differential diagnoses !8 and some commentators
believe that the admissibility of such evidence has become even
more difficult in the wake of Daubert.19 Given the current
13 Id.
14 Callahan, supra note 10, at 163; Sanders & Machal-Falks, supra note 5, at 137
(stating that proving specific causation in toxic tort litigation is "one of the more
difficult causal issues in torts today").
'5 Callahan, supra note 10, at 163.
16 See id.; Sanders & Machal-Falks supra note 5, at 120 (noting that "whenever
there are competing causes for the plaintiffs injury, an expert must attempt a
differential diagnosis before his testimony will be admitted" and that "[c]ourts
accept the general validity of the technique of differential diagnosis"); Gary
Sloboda, Article: Differential Diagnosis or Distortion?, 35 U.S.F.L. REv. 301,
303 (2001) (describing differential diagnoses as "'patient-specific process[es] of
elimination' used to identify the cause of a medical problem by eliminating
possible causes until the most probable cause is isolated").
17 Callahan, supra note 10, at 163; Sanders & Machal-Fulks, supra note 5, at
107.
18 Sloboda, supra note 16, at 304 ("Although medical and scientific knowledge
has advanced significantly in the twentieth century, making medical diagnosis
more precise, the process of differential diagnosis remains 'a mixture of science
and art, far too complicated for its accuracy to be assessed quantitatively or for a
meaningful rate of error to be calculated."').
19 Sanders & Machal-Fulks, supra note 5, at 137.
We believe that it is fair to say that differential diagnosis
testimony generally is looked upon with greater skepticism
than was the case prior to the Daubert revolution. Courts are
less likely to admit the testimony. In part, this is because in
the toxic tort arena plaintiffs are attempting more difficult
causal arguments. We believe it is also because courts have
limitations regarding both general and specific causation, toxic tort
litigants need a tool that can eliminate much of the guesswork by
definitively linking a substance to the injury that it causes.
III. Toxicogenomics
Toxicogenomics is a relatively new science. 20 Once fully
developed, the discipline should greatly improve the current
causation paradigm. A multidisciplinary 2' field focused on
understanding the role of genes in responding to toxicants and
22other stressors, toxicogenomics will eventually advance
toxicology beyond its current "gross endpoints., 23
Fundamental to toxicogenomics is the hypothesis that,
following toxicant exposure and preceding any currently
measurable adverse effect, gene expression is modulated in a
specific and measurable way.24 Once described, these patterns and
become more demanding by requiring better science before
admitting testimony.
Id.
20 Tina Adler, The New Biology, 11: IT ENVTL. HEALTH PERSP.:
ToxICOGENOMIcs A14 (2003) (dating the field to "about 1996, when rapid
genetic sequencing first became possible").
21 Gary E. Marchant, Toxicogenomics and Toxic Torts, 20(8) TRENDS
BIOTECHNOLOGY 329 (2002); Kenneth S. Ramos, EHP Toxicogenomics: A
Publication Forum in the Postgenome Era, 111:1 T ENVTL. HEALTH PERSP.:
TOXICOGENOMICS A13 (2003) ("'Toxicogenomics' describes an emerging
discipline that combines expertise in toxicology, genetics, molecular biology,
and environmental health to elucidate the response of living organisms to
stressful environments.").
22 Erin E. Dooley, txgnet: EHP Toxicogenomics, 111:1 T ENVTL. HEALTH
PERSP.: TOXICOGENOMIcs A 15 (2003).
23 Hisham K. Hamadeh et al., Discovery in Toxicology: Mediation by Gene
Expression Array Technology, 15(5) J. BIOCHEMISTRY MOLECULAR
TOXICOLOGY 231, 231 (2001) (noting "body and organ weight changes and
histopathological observations" as examples of such endpoints); see also
Geistfeld, supra note 4.
24 Michael Waters et al., Systems Toxicology and the Chemical Effects in
Biological Systems (CEBS) Knowledge Base, 111:1 T ENVTL. HEALTH PERSP.:
TOXICOGENOMICS 15, 15 (2003).
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sequences of gene expressions will constitute response
"signatures" unique to specific toxicants or classes of toxicants.25
Two recent studies strongly support this hypothesis.26 In
one, conducted by Zeytun et al., scientists administered a known
toxicant, 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), to mice
and then monitored eighty-three genes for a period following the
exposure.27 A "significant proportion" of the genes examined
showed some form of altered expression following exposure.28 By
studying these patterns of altered expression, researchers may be
able to identify "'finger print' genes, which could serve as
biomarkers for predicting toxicity induced by a specific class of
toxicants.,, 29 In an even more convincing study by Hamadeh, et
al., researchers treated rats with several different chemicals and
monitored a number of genes following the exposures. 30 The
researchers successfully developed distinct gene expression
profiles for each of the classes of chemicals tested, even though
some of those chemicals had the exact same previously measurable
exposure endpoint. 31 These two studies strongly support the
hypothesis that following exposure to a specific toxic substance,
gene modulation will occur in a manner that is both measurable
and predictable.
The initial toxicogenomics studies suggest that the field
holds great promise for toxic tort litigants. Eventually, it could
reduce or eliminate much of the current causation guesswork by
25 Id.
26 Ahmet Zeytun et al., Analysis of 2,3, 7,8-Tetrachlorodibenzo-p-Dioxin-
Induced Gene Expression Profile in Vivo Using Pathway-Specific cDNA Arrays,
178 TOXICOLOGY 241 (2002); Hisham K. Hamadeh et al., Gene Expression
Analysis Reveals Chemical-Specific Profiles, 67 TOXICOLOGICAL SC. 219
(2002).
27 Zeytun et al., supra note 26, at 247.
28 Id.29 Id. (noting, however, this study "failed to discriminate between toxicant
classes based on gene expression profiles"). According to the researchers, this
failure was based on the inclusion of genes that were too sensitive to minor
variations, and the suggestion was made for future researchers to find and use
only those genes that "are altered in a consistent and reproducible fashion." Id.
at 256.
30 Hamadeh et al., supra note 26, at 225.
31 id
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generating evidence that describes how a toxic substance would
affect a person at the molecular level.32 As previously stated, the
promise of toxicogenomics extends to all parties involved in toxic
tort litigation. Commentators,33 defense groups,34 and plaintiffs'
groups35 alike have already recognized its potential importance.
32 Id.
33 See Geistfeld, supra note 4, at 1032 n.54 ("[T]oxicogenomics involves the
laboratory testing of animals or cells to determine the pattern of gene activity
involved upon exposure to a potentially hazardous substance. 'This pattern of
gene activity, at least in theory, should indicate whether the chemical is toxic,
much as DNA fingerprints are used to judge the guilt or innocence of criminal
suspects."'); Gary E. Marchant, Genetics in the Courtroom: Genetics and Toxic
Torts, 31 SETON HALL L. REv. 949, 980 (2001) ("The rapidly growing database
of toxicological information from toxicogenomics should assist tort litigants in
identifying toxic agents and proving the presence or absence of causation.");
Susan R. Poulter, Genetic Testing in Toxic Injury Litigation: The Path to
Scientific Certainty or Blind Alley?, 41 JURIMETRICS J. 211, 211 (2001) ("Rapid
increases in the ability to identify disease genes and disease susceptibility genes
and the expanding field of toxicogenomics suggest that genetic testing could
become an important part of causal proof in toxic injury litigation."); see Gary
E. Marchant, Genetic Susceptibility and Biomarkers in Toxic Injury Litigation,
41 JURIMETRICS J. 67, 75 (2000) ("These new techniques will result in more
rapid screens for toxicity, which is critical given the thousands of commercial
substances for which inadequate toxicity data are available. In addition to
identifying toxic compounds, these techniques will also greatly expand the
understanding of the mechanism of toxicity for many substances, resulting in
more realistic risk estimates. This influx of new toxicological data will
undoubtedly benefit future toxic tort litigants.").
34 Todd M. Hooker, The Brave New World of Toxicogenomics, 16 (11) ENVTL.
COMPLIANCE LITIG. STRATEGIST (April 2001), available at
http://www.lowenstein.com/new/thebraveworldApril2001 .pdf (on file with the
North Carolina Journal of Law & Technology) ("In the long run,
toxicogenomics has the potential to impose the burden on regulators and
plaintiffs' lawyers to prove their positions with documented, confirmed findings
at the human genome level. Substances that do not activate genes whose
activation is necessary (albeit rarely sufficient) to induce a particular toxic
endpoint may be exonerated.").
35 Pat Phibbs, Genomics Will Bring Changes, Soc'Y ENVTL. JOURNALISTS
NEWSL. (Soc'y Envtl. Journalists), at 12-13, Winter 2001, available at
http://www.sej.org (on file with the North Carolina Journal of Law &
Technology) ("The [toxicogenomics] field is expected to have a profound
impact on scientists' understanding of toxicity and illness, public health, toxic
tort litigation, the use of animals in toxicity research, environmental and
FALL 20031 Toxic TORT CAUSATION
A. The Scientific Underpinnings of Toxicogenomics
In a relatively short period, scientists have made a
remarkable amount of progress toward discovering and describing
our molecular makeup. 36 From "[t]he rediscovery of Mendel's
laws of heredity" early in the twentieth century, to the elucidation
of the DNA double helix fifty years ago, and the sequencing and
analysis of individual strands of DNA today, humans have
expanded exponentially the frontiers of genetics over the past
hundred years. 37 Two particular advances in the field promoted
the emergence of toxicogenomics as a discipline.38 First, the rapid
development of DNA sequencing capabilities over the past two
decades has allowed scientists to sequence entire genomes.
Second, researchers are utilizing the vast information contained in
these genome sequences via sophisticated DNA microarrays.
1. Gene Sequencing
One of science's most recent endeavors, and one that still is
very much ongoing, is the development of methodologies and
equipment for rapidly sequencing an organism's DNA.
Sequencing a strand of DNA is a multi-step 39 process resulting in a
occupational regulations, worker's rights, and, perhaps ecological
management.").36 INTERNATIONAL HUMAN GENOME SEQUENCING CONSORTIUM, Initial
Sequencing and Analysis of the Human Genome, 409 NATURE 860 (2001)
[hereinafter Consortium].
37 Id.
38 NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION, MICROARRAYS:
CHIPPING AWAY AT THE MYSTERIES OF SCIENCE AND MEDICINE, at
http://www.ncbi.nlm.nih.gov/About/primer/microarrays.html (last visited Oct.
14, 2003) (on file with the North Carolina Journal of Law & Technology).39 OAK RIDGE NATIONAL LABORATORY, HUMAN GENOME PROJECT
INFORMATION: FACTS ABOUT GENOME SEQUENCING, at
http://www.ornl.gov/hgmis/faq/seqfacts.html (last visited Oct. 16, 2003) (on file
with the North Carolina Journal of Law & Technology).
Chromosomes must first be broken into much shorter
pieces .... Each short piece is used as a template to generate
a set of fragments that differ in length from each other by a
single base that will be identified in a later step .... The
N.C. J.L. & TECH. [VOL. 5
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comprehensive description of the organism's individual base
40
sequence. The sequence of bases in DNA is the most definitive
means of distinguishing among species and among individuals
41
within a species.
DNA sequencing is currently complete for hundreds of
viruses, viroids, plasmids, and organelles, as well as for dozens of
other simple organisms. 42 In 1995, researchers completed the first
fragments in a set are separated by gel electrophoresis ....
New fluorescent dyes allow separation of all four fragments in
a single lane on the gel .... The final base at the end of each
fragment is identified... recreat[ing] the original sequence of
As, Ts, Cs, and Gs for each short piece generated in the first
step. Automated sequencers analyze the resulting
electropherograms, and the output is a four-color
chromatogram showing peaks that represent each of the four
DNA bases .... [C]omputers are used to assemble the short
sequences.., into long continuous stretches that are analyzed
for errors, gene-coding regions, and other characteristics.
Id.
4 0 id.
4' NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION, WHAT IS A
GENOME?, at http://www.ncbi.nlm.nih.gov/About/primer/geneticsgenome.html
(last visited Oct. 14, 2003) (on file with the North Carolina Journal of Law &
Technology).
A DNA chain is made up of four chemical bases: adenine (A)
and guanine (G), which are called purines, and cytosine (C)
and thymine (T), referred to as pyrimidines. Each base has a
slightly different composition, or combination of oxygen,
carbon, nitrogen, and hydrogen. In a DNA chain, every base
is attached to a sugar molecule (deoxyribose) and a phosphate
molecule, resulting in a nucleic acid or nucleotide. Individual
nucleotides are linked through the phosphate group and it is
the precise order, or sequence, of nucleotides that determines
the product made from that gene.
Id.
42 See CONSORTIUM, supra note 36. A large amount of sequencing information
has been made available via public distribution on the Internet. "GenBank is the
NIH genetic sequence database, an annotated collection of all publicly available
DNA sequences" both human and otherwise, and as of February 7, 2003, it
contained 28.5 billion base pairs in 22.3 million sequences. GENBANK,
GROWTH OF GENBANK, at http://www.ncbi.nih.gov/Genbank/genbankstats.html
(last visited Oct. 14, 2003) (on file with the North Carolina Journal of Law &
Technology).
FALL 2003]
N.C. J.L. & TECH.
DNA sequence of a free-living organism and the sequencing of a
number of other more complex organisms rapidly followed.43
The most ambitious DNA sequencing project by far is the
collaborative44 effort to map the human genome. Scientists
published a draft version of the human genome sequence in
February 2001,46 and announced that this enormous effort was
finished on April 14, 2003.4 7 The National Center for
Biotechnology Information currently places the number of known
human genes at about 24,000 not including the genes on the sex
chromosomes.48
43 Emile F. Nuwaysir et al., Microarrays and Toxicology: The Advent of
Toxicogenomics, 24 MOLECULAR CARCINOGENESIS 153, 153-59 (1999).
44 See CONSORTIUM, supra note 36 (noting that the task has involved a
collaborative effort among twenty labs worldwide).
45 Id.
The sequence of the human genome is of interest in several
respects. It is the largest genome to be extensively sequenced
so far, being 25 times as large as any previously sequenced
genome and eight times as large as the sum of all such
genomes. It is the first vertebrate genome to be extensively
sequenced. And, uniquely, it is the genome of our own
species.
Id.
46 Hooker, supra note 34. The race to the finish for the sequencing of the human
genome project had an ample amount of drama involved. Two labs ultimately
published simultaneously in separate journals. Celera Genomics, a
biotechnology laboratory in Rockville, Maryland published the sequenced
human genome in SCIENCE and the government-sponsored Human Genome
Project published in NATURE.4 7 NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION, GENOME
SEQUENCING, at http://www.ncbi.nlm.nih.gov/genome/seq/ (last visited Oct. 14,
2003) (on file with the North Carolina Journal of Law & Technology)
[hereinafter GENOME SEQUENCING].
4 8 NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION, HUMAN GENOME
RESOURCES, at http://www.ncbi.nlm.nih.gov/genome/guide/human (last visited
Oct. 17, 2003) (on file with the North Carolina Journal of Law & Technology).
['VOL. 5
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2. Microarrays
Given the vast size of a DNA molecule4 9 and the potential
amount of information available therein, a research tool capable of
exploiting such large quantities of information is necessary.
Microarrays are such a tool. 50 A microarray is typically either a
glass slide or a computer chip that has had a specific arrangement
of known gene sequences either spotted onto it or engineered onto
it, respectively.5'
Although the origins of microarrays can be traced to the
mid to late 1980s, 52 today's microarray is highly evolved and
capable of vastly superior analytical feats. As one researcher
noted, while "[t]he simultaneous examination of a hundred genes is
descriptive; the simultaneous examination by comparison and
clustering of tens of thousands of genes is a new way to do
science." 53 Another researcher explained, "the microarray
approach, which allows the monitoring of expression levels of
thousands of genes simultaneously, is a tool of unprecedented
power for use in toxicology studies. 54
Microarrays typically come in two varieties:
"oligonucleotide-based arrays and [complementary DNA or]
cDNA arrays., 55 Given the increasing commercial availability of
microarrays 56 and enhanced capacity to simultaneously monitor
49 See GENOME SEQUENCING, supra note 47; see also Press Release, NATIONAL
HUMAN GENOME RESEARCH INSTITUTE, INTERNATIONAL CONSORTIUM
COMPLETES HUMAN GENOME PROJECT (Apr. 14, 2003) (noting that human DNA
is comprised of three billion base pairs) at http://www.genome.gov/11006929
(on file with the North Carolina Journal of Law & Technology).
50 Charles W. Schmidt, Toxicogenomics, 111: IT ENVTL. HEALTH PERSP.:
TOXICOGENOMICS A20, A22 (2003).
51 Philip M. lannaccone, Toxicogenomics: "The Call of the Wild Chip," 109(1)
ENVTL. HEALTH PERSP. (editorial) (2001).
52 Roger Ekins & Frederick W. Chu, Microarrays: Their Origins and
Applications, 17(6) Trends in Biotechnology 217 (1999); see also Adler, supra
note 20.
53 See Iannaccone, supra note 51.
54 Nuwaysir, supra note 43, at 153.
55 Id.; see also Hamadeh, supra note 23, at 231.
56 William D. Pennie et al., The Principles and Practice of Toxicogenomics:
Applications and Opportunities, 54 TOXICOLOGICAL SCI. 277, 277 (2000)
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very large numbers of genes, most of the current toxicogenomics
research utilizes cDNA microarrays.
B. An Example of Microarray Application in
Toxicogenomics
Experimentation with cDNA microarrays involves three
broad steps: design of the microarray, application of the
microarray, and analysis of data. For purposes of explanation, this
article will examine a simplistic hypothetical scenario. Assume
that a researcher working at a cereal company has developed a new
food additive, but he is concerned that it might adversely affect the
liver. For simplicity in this hypothetical, assume also that this
researcher was only concerned with discovering whether one
particular gene ("Target Gene") would be expressed in liver tissue
following exposure to this suspected hepatotoxin. 57
1. Slide Design
The first step in the process, microarray design, is quickly
becoming a major industry.58 A necessary pre-design step involves
researching whether anyone holds a patent on the Target Gene, and
then attempting to obtain licensing agreements if necessary. At
least some of the companies developing microarrays for
(noting that the manufacture of microarrays for specific purposes by
"commercial vendors; pharmaceutical companies, and academic institutions" is
becoming more and more common).5 7 NATIONAL LIBRARY OF MEDICINE, TOXICOLOGY GLOSSARY: H, at
http://www.sis.nlm.nih.gov/ToxTutor/Toxl/glossh.htm (defining hepatotoxin as
"[a] systemic poison whose target organ is the liver") (last visited Oct. 18, 2003)
(on file with the North Carolina Journal of Law & Technology)
58 Kristin Lewotsky, Growing, Growing, Gone: The Biotechnology Market is
Poised to Soar, OE MAG., Feb. 2002, at 18-19, available at
http://oemagazine.com/fromTheMagazine/feb02/pdf/specialfocus.pdf (on file
with the North Carolina Journal of Law & Technology). Microarrays are "a
high-growth area, with applications in industries like biotechnology, food and
beverage, and life science .... ." Id. Growth estimates suggest that the market
will grow "from $400 million in 2000 to $1 billion by 2005 .... The protein-
chip market alone ... will grow from the 2000 figure of $44 million to reach
$490 million by 2006." Id.
N.C. J.L. & TECH. [VOL. 5
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commercial use resent this step 59 and have lobbied for legislation
that would allow non-commercial researchers to use such
sequences without first obtaining a license. For purposes of this
hypothetical, assume the Target Gene has not been patented.
To prepare the microarray slide, a researcher would collect,
isolate, and reverse transcribe single-stranded mRNA coding for
the Target Gene to produce cDNA. 61 The researcher then would
degrade the mRNA from the newly formed mRNA-cDNA
molecule, and the single-stranded cDNA molecule would serve as
a template for the formation of a double-stranded DNA molecule.
62
Next, she would multiply via polymerase chain reaction ("PCR")
the resultant DNA molecule and purify it.63 Finally, the researcher
would denature the double-stranded DNA so that many single
strands of DNA could be "spotted" onto the slide. 64 In the end,
exactly half of the single stranded DNA molecules on the slide
would be complementary to cDNA produced via reverse
transcription of the Target Gene mRNA.
59 "'There should be no patenting of gene sequences, period. They were
invented by nature,' said Barbara Caulfield, general counsel for [Affymetrix].
'This a position Affymetrix feels strongly about."' Tom Abate, Do Gene
Patents Wrap Research in Red Tape?, SAN FRANCISCO CHRON., Mar. 25, 2002,
available at http://www.sfgate.com/cgi-bin/article.cgi?f=c/a/2002/03/25
/BU97425.DTL (on file with the North Carolina Journal of Law &Technology).
60 Genomic Research and Diagnostic Accessibility Act of 2002, H.R. 3967
§§ (j)(1), (2)(E), 107th Cong. (2002). The bill is very broad regarding who is
considered a researcher. "It shall not be an act of infringement for any
individual or entity to use any patent for or patented use of genetic sequence
information for purposes of research." Id. (emphasis added). "[T]he term
'research' means a systematic investigation, including research development,
testing, and evaluation, designed to develop or contribute to generalizable
knowledge." Id.
61 NATIONAL HUMAN GENOME RESEARCH INSTITUTE, MICROARRAY PROJECT, at
http://research.nhgri.nih.gov/microarray/Protocols.pdf (last visited Oct. 1, 2003)
(on file with the North Carolina Journal of Law & Technology) [hereinafter
NHGRI].
62 NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION, ESTs: GENE
DISCOVERY MADE EASIER, at http://www.ncbi.nlm.nih.gov/About
/primer/est.html (last visited Oct. 14, 2003) (on file with the North Carolina
Journal of Law & Technology) [hereinafter ESTs].
63 NHGRI, supra note 61.
64 id.
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The researcher would then coat the slide with poly-L-
lysine, which would produce a "surface that is both hydrophobic
and positively charged. The hydrophobic character of the surface
minimizes spreading ... and the charge" helps to position the
single strands of DNA on the slide surface so that hybridization is
enhanced. 65 The slide is designed such that when single-stranded
cDNA coding for the Target Gene is applied, that cDNA strand
will hybridize with the single-stranded DNA already on the slide.
While this hypothetical is focusing on only a single Target Gene
for illustration purposes, remember that the revolutionary impact
of microarrays is their ability to simultaneously monitor tens of
thousands of genes on a single slide via these same or similar
techniques.66
2. Application of the Newly Designed
Microarray in Target Gene Experimentation
Following preparation of the microarray, a researcher
would harvest cells from both the unexposed liver tissue and the
hepatotoxin-exposed liver tissue.67 She would then isolate and
purify the total RNA present in those cell samples. Each of these
total RNA mixtures would undergo reverse transcription to
produce the cDNA molecules to be applied to the slide. 69 The
researcher would differentially label the two sets of cDNA
molecules during reverse transcription to distinguish between the
unexposed and hepatotoxin-exposed samples.
Reverse transcription is a process whereby single-stranded
mRNA is used as a template to produce single-stranded cDNA.
Reverse transcription begins when a primer attaches to an mRNA
molecule. To form the cDNA molecule, an enzyme, usually
65 id.
66 See supra text accompanying notes 52-53.
67 Emile F. Nuwaysir, Design, Generation, and Used of cDNA Microarrays on
Glass, SOT2000: Continuing Education Course PM-16, Toxicogenomics in the
Trenches (Mar. 19, 2000) (unpublished presentation materials), available at
http://dir.niehs.nih.gov/microarray/figuresibackground.pdf (on file with the
North Carolina Journal of Law & Technology).
68 NHGRI, supra note 61.
69 Nuwaysir, supra note 43.
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reverse transcriptase, responds to the primer and begins
sequentially adding deoxynucleotide triphosphates (dNTPs) that
are complementary to the bases on the mRNA strand. To ensure
that the entire cDNA molecule is accurately produced, equal
amounts of four dNTPs, typically dATP, dTTP, dCTP, and dGTP,
would be present in the solution where the reverse transcription
was occurring. 70 Thus, reverse transcription would occur in a
solution consisting primarily of (1) the RNA templates, (2) the
initiation primer, (3) reverse transcriptase, and (4) enough of each
dNTP such that when reverse transcriptase, in extending the cDNA
strand, seeks to add a particular dNTP that is complementary to the
base on the mRNA strand, there are sufficient quantities of each
dNTP present in the solution for it to be able to effectively do so.
To label these forming cDNA strands, the researcher would
tag one of the four available dNTPs with a fluorescent dye 7 1 so that
the dye would be incorporated into the cDNA molecule each time
that particular dNTP was added by the reverse transcriptase. 72 To
differentiate between the two samples, each reverse transcription
process would use the same dNTP, but would be tagged with a
70 OREGON HEALTH & SCIENCE UNIVERSITY DIVISION OF MEDICAL
INFORMATICS AND OUTCOMES RESEARCH, REVERSE TRANSCRIPTION PROTOCOL,
at http://medir.ohsu.edu/-geneview/protocol/Reverse%20Transcription%20
Protocol.pdf (last visited Oct. 17, 2003) (on file with the North Carolina Journal
of Law & Technology); ESTs, supra note 62 (noting that the dNTPs generally
used are dATP, dTTP, dCTP, and dGTP, where "A" represents adenine, "T"
represents thymine, "C" represents cytosine, and "G" represents guanine). In
the labeling step, however, a number of protocols utilize dUTP instead of dTTP,
where "U" represents Uracil. Regardless, adenine is always complementary to
thymine and uracil, and cytosine is always complementary to guanine. Id.
71 See, e.g., Hamadeh, supra note 23, at 232.
72 lannaccone, supra note 51. This is one of the most common methods of
incorporating a fluor into the sequence that is then detectable post-transcription,
but there are certainly a number of variations on this theme. For examples of
other methods, see JOSEPH DERISI, AMINO-ALLYL DYE COUPLING PROTOCOL, at
http://www.microarrays.org/pdfs/amino-allyl-protocol.pdf (June 2001)
(describing a method of incorporating an amino-allyl during the transcription
process which could then be labeled with a dye post-transcription) (on file with
the North Carolina Journal of Law & Technology); Affymetrix, Array
Manufacturing, at http://www.affymetrix.com/technology/ge-analysis
/index.affx (last visited Oct. 11, 2003) (diagramming use of biotin-labeled
cRNA) (on file with the North Carolina Journal of Law & Technology).
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different fluorescent substance. For example, the RNA from the
unexposed cells might undergo reverse transcription in the
presence of Cy5-dCTP, which would fluoresce red when excited
by one laser, and the RNA from the hepatotoxin-exposed cells
might undergo reverse transcription in the presence of Cy3-dCTP,
which would fluoresce green when excited by another laser.73 In
this scenario, each time the reverse transcriptase came to a guanine
in the RNA strand, it would add a fluorescently tagged dCTP
(cytosine is complementary to guanine) to the forming cDNA
strand.
The researcher would then mix together the two sets of
differentially tagged cDNA strands and apply them to the slide.74
If the Target Gene were expressed in either of the two samples, the
cDNA would hybridize with the single stranded DNA molecules
already present on the slide.75 The cDNA that did not hybridize
would then be washed off the slide.76 Different lasers would be
used to excite the fluorescent tags within any hybridized strands,
eliciting a range of fluorescent responses that could be detected
and quantified in an automated reader. 77
3. Analyzing the Data from the Microarrays
After analysis of the different fluorescent responses, the
color variations would quantify if, and to what extent, the Target
Gene was expressed in the tissues of the hepatotoxin-exposed and
unexposed liver samples. Since the original hypothesis in this
hypothetical was whether the Target Gene would be expressed
following hepatotoxin exposure, these data would be sufficient to
test that hypothesis. However, a researcher could not conclude,
based solely on the results of this experiment, that any measurable
gene expression was an indicator of toxicity. Indeed, one of the
major difficulties facing toxicogenomics is determining what, if
73 Hamadeh, supra note 23, at 232.
74 Nuwaysir, supra note 67, slide 6.
75 id.
76 NHGRI, supra note 61.
77 lannaccone, supra note 51.
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anything, a particular gene expression or pattern of gene
expressions indicates.
78
i. Phenotypic Anchoring
To improve the utility of toxicogenomics data in general,
and to make it valuable to litigants in toxic tort cases, it is essential
to tie gene expression patterns to standard toxicology indices.79
Phenotypic anchoring refers to the correlation of the gene
expression profile data with well-established toxicity data such as
"toxicant class, chemical structure, pathological or physiological
response, or other validated indices" of toxic response.80 Linking
these sets of data is currently one of the foremost goals of the
toxicogenomics community. 81 Although researchers are making
substantial progress in this direction, the relationship between gene
expression and toxic impact is still uncertain in most cases.
82
ii. Bioinformatics
Another formidable challenge facing toxicogenomics is the
efficient management of the vast amount of information produced
83from microarrays. In addition to simultaneously monitoring tens
of thousands of genes, a number of other factors make data
78 Schmidt, supra note 50, at A23 (noting that the particular gene expression
could indicate harmful, harmless, or protective effects).
79 Waters, supra note 24, at 17 (listing several tissue pathologies and enzyme
level changes as examples of "well-defined, conventional indices of toxicity").
8 0 NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES, GOALS OF THE
NCT, at http://www.niehs.nih.gov/nct/goall.htm (last visited Oct. 18, 2003) (on
file with the North Carolina Journal of Law & Technology). "For example,
experiments can be designed to correlate gene expression patterns with liver
pathologies such as hepatomegaly (enlarged liver), hepatocellular necrosis
(death of liver cells or tissues) or inflammation. It is also possible to look for
correlative patterns-for example in enzyme levels-in liver and other tissues or
cells such as blood. Changes in serum enzymes provide diagnostic markers of
organ function that are commonly used in medicine and in toxicology." Id.
81 Waters, supra note 24, at 17.
82 Schmidt, supra note 50, at A23.
83 Hamadeh, supra note 23, at 232.
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analysis more complex. 84 For example, the gene expression of a
previously unexposed animal following an acute dose of a single
toxin may be markedly different from that of an animal that is
exposed to multiple toxins or that has developed an immune or
other adaptive response based on previous exposures to the same
or similar toxins. With the expected onslaught of toxicogenomics
research during the next decade, bioinformatics will be a critical
tool that researchers will use to better manage the complex data
generated from such studies.
85
IV. Admissibility of Toxicogenomics Evidence
A. The Frye Standard
Following a 1923 decision by the Court of Appeals for the
D.C. Circuit, 86 most state and federal courts addressed any proffer
of scientific evidence by asking whether the methodology used to
generate that evidence was "sufficiently established to have gained
general acceptance in the particular field in which it belongs."
87
84 Schmidt, supra note 50, at A23.
People are generally exposed to many compounds
simultaneously, often on a chronic or intermittent basis.
Eventually... toxicogenomics will have to address more
realistic exposure scenarios. These pathways are much more
complex .... Any evaluation of chronic exposures must
contend with the added dimensions of time, adaptive response,
and cellular repair. "The signals for each of these processes
are masked in the complexity of the response .. " "With
repeat dosing, it all becomes much more intricate."
Id.
85 Waters, supra note 24, at 20; Hamadeh, supra note 23, at 232.
Bioinformatics in gene expression analysis deals with tasks
including spot location, definition, and intensity calculations
from raw scanned images, transformation of data sets into
more easily quantifiable forms, application of analysis tools to
extract associations between gene expression levels, and
extraction of information from analyses that facilitate the
development of new testable hypotheses.
Hamadeh, supra note 23, at 232.
86 Frye v. United States, 293 F. 1013 (D.C. Cir. 1923).
87Id. at 1014.
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While this "Frye standard" is intuitively satisfying since it leaves
the judgment of what constitutes quality science up to the scientific
community, critics have attacked the Frye standard from three
directions. First, the standard under Frye would necessarily
exclude new or novel scientific evidence, regardless of its actual
reliability or relevance. 88 Second, the vagueness of the Frye
language gave courts too much control over admitting or excluding
evidence.89 And third, at least in federal courts, Frye did not
conform to the Federal Rules of Evidence enacted in 1975.90
B. Daubert and Federal Rule of Evidence 702
In 1993, the Supreme Court announced a new evidentiary
standard for the federal courts9' in Daubert v. Merrel Dow
Pharmaceuticals, Inc. 92 The key change under Daubert is that
judges now are required to act as gatekeepers, deciding whether
"an expert's testimony both rests on a reliable foundation and is
relevant to the task at hand., 93 Shortly after Daubert was decided,
88 Craig Lee Montz, Trial Judges as Scientific Gatekeepers After Daubert,
Joiner, Kumho Tire, and Amended Rule 702: Is Anyone Still Seriously Buying
This?, 33 UWLA L. REv. 87, 92 (2001).
89 ld.
90 Id.
91 See Joseph T. Walsh, The Evolving Standards ofAdmissibility of Scientfic
Evidence, 26(3) JUDGES J. 33, 35 (1997) (explaining that "[t]he Supreme Court's
ruling in Daubert was issued under its supervisory power and thus is binding
only on federal courts"). For several interesting attempts at describing how
states have reacted to Daubert, see Joseph G. Eaton, Survival of the "Fryest ": A
review of Recent Supreme Court Decisions Analyzing Frye's General
Acceptance Standard and a 50 State Survey of the Standards for Admissibility of
Expert Testimony, Toxics L. REP. 8 (2002) (listing 17 states that have
"explicitly adopted" Daubert and noting that several other states apply a similar
standard); Montz, supra, note 88, at 96 (stating that by 1997, twenty eight states
were using Daubert or a similar standard); Alice B. Lustre, Annotation, Post-
Daubert Standards for Admissibility of Scientific and Other Expert Evidence in
State Courts, 90 A.L.R. 5th 453 (2001) (listing twenty-six states which apply
Daubert or a similar test); Bert Black, Expert Evidence in the Wake of the
Daubert-Joiner-Kumho Trilogy, ALI-ABA CONT. LEG. EDUC. 125 (1999)
(listing twenty-two states as having adopted Daubert).
92 509 U.S. 579, 587-88 (1993).
93 Id. at 597-98. Daubert requires the judge to
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two additional Supreme Court decisions further clarified the new
standard. In General Electric Co. v. Joiner,94 the Court held that
appellate courts must apply the abuse of discretion standard when
reviewing a trial court's decision to admit or exclude testimony
under Daubert. In Kumho Tire Co. v. Carmichael,95 the Court held
that Daubert was applicable to all expert testimony and not limited
to scientific expert testimony. Together, these three cases
comprise what has been called either "Daubert and its progeny" or
simply the "trilogy." 96 The trilogy is now largely codified as
Federal Rule of Evidence 702:
If scientific, technical, or other specialized
knowledge will assist the trier of fact to understand
the evidence or to determine a fact in issue, a
witness qualified as an expert by knowledge, skill,
experience, training, or education, may testify
thereto in the form of an opinion or otherwise, if (1)
the testimony is based upon sufficient facts or data,
(2) the testimony is the product of reliable
principles and methods, and (3) the witness has
determine if the evidence to be admitted (1) qualifies as
scientific knowledge, and (2) will aid the jury. Deciding
whether the evidence qualifies as scientific knowledge is a
question of reliability, in which the judge considers: (a)
"whether [the theory or technique] can be (and has been)
tested;" (b) "whether the theory or technique has been
subjected to peer review and publication;" (c) "the known or
potential rate of error;" and (d) "general acceptance" of the
method. The second prong of the Daubert test is one offit;
the judge must decide if the evidence is relevant to the jury's
determination of an issue of fact.
Callahan, supra note 10, at 151.
94 522 U.S. 136 (1997).
95 526 U.S. 137 (1999).
96 See Margaret A. Berger, Upsetting the Balance Between Adverse Interest:
The Impact of the Supreme Court's Trilogy on Expert Testimony in Toxic Tort
Litigation, 64 LAW & CONTEMP. PROBS. 289 (2001); Catherine E. Brixen &
Christine E. Meis, Codifying the "Daubert Trilogy": The Amendment to
Federal Rule of Evidence 702, 40 JURIMETRICS J. 527 (2000); Lorie S. Gildea,
Sifting the Dross: Expert Witness Testimony in Minnesota After the Daubert
Trilogy, 26 WM. MITCHELL L. REv. 93 (2000).
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applied the principles and methods reliably to the
facts of the case.
1. Application of the Trilogy to Toxicogenomics
Evidence
Some commentators have observed that while Daubert may
"appear to establish a clear standard of admission, in application it
has proved cumbersome." 98 The difficulty of applying Daubert is
particularly apparent "in toxic tort litigation, where proof of
medical causation is heavily dependent on expert scientific
testimony."
99
At least one commentator has argued that evidence
produced from molecular epidemiology studies should be
admissible in toxic tort litigation under Daubert.1
00
Molecular epidemiology attempts to evaluate the
damage done by toxic substances by looking for
certain markers of exposure. Molecular
epidemiological research involves finding new
markers and determining the 'right' marker to
measure a particular toxin. These markers or
biomarkers are based on the premise that there are
several stages of molecular events that eventually
lead to cancer.
0 1
9 7 FED. R. EvID. 702.
98 Callahan, supra note 10, at 156-57.
99 Id.
'
00 Id. at 151.
101 Id.
Biomarkers can be used to indicate exposure from a particular
toxin at three stages of events: (1) internal dose of the toxin,
seen in products of the breakdown of the toxin called
metabolites, (2) molecular dose seen in the presence of an
adduct, a metabolite bonded to another molecule in the body,
or (3) early signs of disease in the form of mutations and other
damaging genetic effects.
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Molecular epidemiology is thus similar to toxicogenomics since
both fields attempt to directly link exposure to injury via molecular
markers. 1 02
i. General Causation
As previously stated, 10 3 to prove general causation,
epidemiological evidence often is required unless there are
"controlled experimental studies tying the toxin to the disease."' 0 4
Such studies would be more valuable to toxic tort litigants than
standard epidemiological studies that do not establish a direct
causal link but merely serve to statistically demonstrate that "the
occurrence of the disease is more common among those exposed to
the toxin than those who are not.' 1 5 If molecular epidemiology
and toxicogenomics data could directly tie a particular toxin to a
specific injury, such evidence might supplant epidemiology studies
altogether.
Assuming preservation of the status quo, however, the
question becomes whether judges would allow such molecular
evidence to establish general causation in lieu of standard
epidemiology studies. Given the name of the discipline, some
judges might view molecular epidemiology evidence favorably,
and as just another type of epidemiology evidence. The "unknown
rate of error" in the field, though, might also lead some judges to
reject the evidence under Daubert's reliability prong. 106 Unlike
molecular epidemiology evidence, however, toxicogenomics
evidence likely would not be seen as just another type of
epidemiology evidence, and it suffers from similar reliability
problems. 1
07
102 Marchant, supra note 21, at 330 (citing among others, Callahan, supra note
10, and stating that although "[t]here are no reported toxic tort cases to date in
which toxicogenomic data have had a significant role. Legal commentators
have, nevertheless, begun to focus on potential tort applications of genomic
techniques.").
103 See supra Part II.A, note 7.
104 Callahan, supra note 10, at 161.
105 Id.
106Id. at 161-62.
107 Marchant, supra note 21, at 332.
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Additionally, "[b]ecause techniques involved in microarray
studies are not yet standardized, researchers face technical
difficulties at different stages when performing" experiments with
them. 108 Given the lack of standardization among researchers, the
reliability of toxicogenomics studies at this point is difficult to
surmise. With additional toxicogenomics testing, particularly in
conjunction with and validated by classical toxicity studies,, °9
however, courts might be more apt to look favorably upon such
evidence. "10
There are many scientific and legal issues relating to the
validation, quality control and significance of toxicogenomic
data that remain to be addressed before the data should be
applied in a non-research context. Toxic tort litigants have
very little incentive to wait for these uncertainties to be fully
resolved because, unlike scientists or regulators who have the
luxury of revisiting their decisions, litigants are one-time
players in a high-stakes game. Therefore, there will be
temptation to use toxicogenomic data in toxic tort lawsuits
prematurely, just as has occurred in the past with other types
of novel scientific evidence.
Id.; see also Schmidt, supra note 50, at A25.
Regulatory agencies are also grappling with toxicogenomics
issues. In June 2002, the ... (EPA) issued its first guidelines
for using genomics data for the standard-setting process ....
[T]he agency opined that toxicogenomics will potentially have
an 'enormous impact on our ability to assess the risk from
exposure to stressors and ultimately to improve our risk
assessments,' . . . [b]ut 'the relationships between changes in
gene expression and adverse effects are unclear a this time and
may be difficult to evaluate.' . . . The... (FDA) is also
closely watching.., the field... [and concerned about] the
difficulty of linking microarray results to adverse effects.
Id.
108 Hamadeh, et al., supra note 23, at 239; see also Schmidt, supra note 50, at
A23-25 (noting that at least one committee, the Health and Life Sciences
Institute of the International Life Sciences Institute (ILSI), rejected adopting
standardized methods at this point since "[t]he techniques are still evolving at a
rapid pace" and adopting such standards might constrain research efforts).
109 See supra Part III.3.B. 2.110 Kyle Kolaja, Toxicogenomics: Where Are We and Where Do We Go Now?,
GENOMICS PROTEOMICS, Sept. 2002, 11.
Most preclinical toxicogenomic work to date has been either
database building with prototype nondevelopment candidates
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ii. Individual Causation
Regarding individual causation,"l ' both molecular
epidemiology and toxicogenomics move beyond the differential
diagnosis paradigm of merely ruling out other potential causes of
the disease, since they seek to demonstrably link a particular toxin
to a particular disease. Since "[m]olecular epidemiological studies
establish that certain toxins cause specific molecular and genetic
changes that eventually lead to [disease],... these changes could
be used as markers for exposure to the toxin." 112 The presence or
absence of such a marker would seemingly be valuable individual
causation evidence. Similarly, in toxicogenomics, "DNA
microarrays could be used to identify or confirm the category of
toxic substances to which an individual was exposed, based on
gene expression profiling."11 3 The expression or the absence of
expression of certain genes in an individual could eventually serve
as evidence to either establish or rebut the claim that exposure to a
particular toxin caused the specific injury.
iii. Admissibility
As an emerging science capable of producing remarkably
complex evidence, the admissibility of toxicogenomics data in
toxic tort litigation still is an open question." 4 At this point,
or discovery-stage screening of compounds. A significant step
forward will be the use of toxicogenomics data in studies
intended to support registration. Currently, the FDA is leery
of the use of data in this format, but it may be acceptable if the
data support conclusions based on other classical endpoints of
toxicity.
Id.
1 See supra Part II.B.
112 Callahan, supra note 10, at 148.
113 Marchant, supra note 21 ("A key toxicogenomic technique is to profile
(using a DNA microarray or 'gene chip') the cell-wide changes in gene
expression following exposure to toxins. This approach creates the potential to
provide a molecular 'fingerprint' of exposure or toxicological response to
specific classes of toxic substances.").
114 A Westlaw search of all federal and state cases on October 21, 2003 for
"toxicogenomic!" or "microarray!" returned only two cases. Neither case
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however, judges would be well advised to deem toxicogenomics
evidence inadmissible based on relevancy until more research
linking gene expression pathways to specific toxic endpoints is
available! 15
V. Conclusion
Dealing with causation in toxic tort litigation is currently a
frustrating and cumbersome process for all parties involved. With
the emergence of toxicogenomics, litigants soon may be able to
trace discrete gene pathways from exposure to injury, thereby more
definitively establishing or ruling out a causal connection between
the particular substance and the specific injury in the plaintiff.
Given the developmental stage of the science, however, judges
controlled by Daubert must closely scrutinize any proffer of
toxicogenomics evidence to ensure that it has been sufficiently
linked to known toxicity endpoints.
involved the introduction or attempted introduction of toxicogenomics evidence
to establish causation in a toxic torts case. Both pertained to disputes involving
microarray manufacturers.
115 Waters, supra note 24, at 15 (describing the progress and goals of the
National Center for Toxicogenomics CEBS Knowledge Base that will ultimately
combine data from a number of disciplines within one searchable database).
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